Elutia Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $12.1M-16.1% YoYTTM through 30 Jun 2026
Net Income $51.8MTTM through 30 Jun 2026
Free Cash Flow -$46MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 53.7% |
| EBITDA Margin | -200.8% |
| Operating Margin | -218.9% |
| Net Margin | 426.9% |
Returns
192.9%ROE
85.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.22x
Net Debt-$36.4Mnet cash position
Cash & Equivalents$19.9M
Quality Metrics
Altman Z-Score-6.61
Piotroski F-Score4 / 9
FCF Margin-379.3%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $12.3M
Diluted EPS$0.99TTMFY2025: $1.16
Dividend
No dividend
Capital Allocation
R&D Spend$6.8M
Capex Intensity16.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Women's Health | $9.1M | -21.2% | View detailsStrategic options are being explored for the patented SimpliDerm product line. |
| Cardiovascular | $3.2M | +8.3% | View detailsFocusing on remaining cardiovascular products and the development of NXT-41/NXT-41x. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.